GSK Provides an Update on CALM-1 and CALM-2 Phase III Trials for Camlipixant in Refractory Chronic Cough (RCC)

Дата публикации: 17-07-2026 20:07:17

London, UK -- 17 July 2026 GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and CALM-2 phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant (a P2X3 receptor antagonist) in adults with...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)	0	4.32	17-07-2026
2	Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer.	0	18.59	12-08-2026
3	Camurus Provides Regulatory Update on the US NDA for CAM2029 (Oclaiz™) in Acromegaly	0	13.28	10-06-2026
4	Camurus’ NDA Resubmission for CAM2029 in Acromegaly Accepted for Review by the US FDA	0	10.06	17-07-2026
5	Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA	0	8.85	28-04-2026
6	Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease	0	17.79	21-07-2026
7	New Drug Application for Neladalkib in TKI Pre-Treated Advanced ALK-Positive NSCLC Accepted for Filing with Priority Review by the FDA	0	17.4	27-05-2026
8	Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy	0	14.49	05-08-2026
9	GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population	0	15.79	10-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 7.48. Источник: www.drugs.com.